Last reviewed · How we verify
Dupilumab Injectable Product
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of interleukin-4 and interleukin-13 to reduce type 2 inflammatory responses.
Dupilumab is a monoclonal antibody that blocks the IL-4 receptor alpha subunit, inhibiting signaling of interleukin-4 and interleukin-13 to reduce type 2 inflammatory responses. Used for Moderate-to-severe atopic dermatitis, Moderate-to-severe asthma with type 2 inflammation, Chronic rhinosinusitis with nasal polyps.
At a glance
| Generic name | Dupilumab Injectable Product |
|---|---|
| Also known as | Rhinovirus |
| Sponsor | University of Virginia |
| Drug class | IL-4 receptor antagonist monoclonal antibody |
| Target | IL-4 receptor alpha (IL-4Rα) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Dupilumab binds to IL-4 receptor alpha, a shared component of IL-4 and IL-13 signaling pathways that drive type 2 inflammation. By blocking this receptor, it suppresses the production of IgE and inflammatory cytokines, reducing eosinophil recruitment and activation. This mechanism addresses the underlying pathophysiology of multiple type 2 inflammatory conditions including atopic dermatitis, asthma, and eosinophilic diseases.
Approved indications
- Moderate-to-severe atopic dermatitis
- Moderate-to-severe asthma with type 2 inflammation
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic esophagitis
- Eosinophilic granulomatosis with polyangiitis
Common side effects
- Injection site reactions
- Conjunctivitis
- Headache
- Oropharyngeal pain
- Upper respiratory tract infection
Key clinical trials
- A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines (PHASE3)
- Investigating Dupilumab's Effect in Asthma by Genotype (PHASE4)
- Mechanisms of Smell Improvement With Dupilumab. (PHASE4)
- Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents (PHASE2)
- Dupilumab De-escalation in Pediatric Atopic Dermatitis (PHASE4)
- Dupilumab Therapy in Nephrotic Syndrome in Children (PHASE2)
- Dupilumab Therapy for EGIDs
- Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dupilumab Injectable Product CI brief — competitive landscape report
- Dupilumab Injectable Product updates RSS · CI watch RSS
- University of Virginia portfolio CI